Generic drugs are increasingly marketed around the world to the detriment of their quality. The objective of this work was therefore to carry out a bioequivalence study between the originator Zithromax, a drug for the treatment COVID-19, and its generic Azithral. This bioequivalence study is based on the quality control of generic and originator azithromycin tablets, which is carried out after validation of the azithromycin assay method, and essentially on pharmaco-technical tests (mass uniformity, breakability, disintegration, dissolution in vitro). By referring mainly to different pharmacopoeias, the tests have shown that the quality of generic tablets is acceptable but seems to be less satisfactory than that of originator tablets.
Youcef Hattab (Thu,) studied this question.